Erratum: Amino Acid Polymorphisms in Hepatitis C Virus Core Affect Infectious Virus Production and Major Histocompatibility Complex Class i Molecule Expression (Scientific Reports 5 13994 10.1038/srep13994);Amino Acid Polymorphisms in Hepatitis C Virus Core Affect Infectious Virus Production and Major Histocompatibility Complex Class i Molecule Expression

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Tasaka Fujita, Megumi ^a,b   Sugiyama, Nao ^a   Kang, Wonseok ^c   Masaski, Takahiro ^a   Murayama, Asako ^a   Yamada, Norie ^a   Sugiyama, Ryuichi ^a   Tsukuda, Senko ^a   Watashi, Koichi ^a   Asahina, Yasuhiro ^b   Sakamoto, Naoya ^d   Wakita, Takaji ^a   Shin, Eui Cheol ^c   Kato, Takanobu ^a  

^a NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

^b TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^c Korea Advanced Institute of Science and Technology (KAIST)   (South Korea)

^d HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTIVIRUS AGENT; CORE PROTEIN; HLA ANTIGEN CLASS 1; NUCLEOCAPSID PROTEIN, HEPATITIS C VIRUS; PROTEIN KINASE R;

CELL LINE; GENETICS; GENOTYPE; HEPACIVIRUS; HUMAN; METABOLISM; PHENOTYPE; PHOSPHORYLATION; PHYSIOLOGY; SITE DIRECTED MUTAGENESIS; VIRUS REPLICATION;

ANTIVIRAL AGENTS; CELL LINE; EIF-2 KINASE; GENOTYPE; HEPACIVIRUS; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; INTERFERON-ALPHA; MUTAGENESIS, SITE-DIRECTED; PHENOTYPE; PHOSPHORYLATION; VIRAL CORE PROTEINS; VIRUS REPLICATION;

EID: 84941585533     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep17208     Document Type: Erratum

References (53)

1. Liang, T. J., Rehermann, B., Seeff, L. B. & Hoofnagle, J. H. Pathogenesis, natural history, treatment, and prevention of hepatitis C. Ann. Intern. Med. 132, 296-305 (2000).
2. Shepard, C. W., Finelli, L. & Alter, M. J. Global epidemiology of hepatitis C virus infection. Lancet Infect. Dis. 5, 558-567, doi: 10. 1016/s1473-3099(05)70216-4 (2005).
3. Hoofnagle, J. H. et al. Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon. A preliminary report. N. Engl. J. Med. 315, 1575-1578, doi: 10. 1056/NEJM198612183152503 (1986).
4. Ghany, M. G., Strader, D. B., Thomas, D. L., Seeff, L. B. & American Association for the Study of Liver, D. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 49, 1335-1374, doi: 10. 1002/hep. 22759 (2009).
5. Zeuzem, S. et al. Expert opinion on the treatment of patients with chronic hepatitis C. J. Viral Hepat. 16, 75-90, doi: 10. 1111/j. 1365-2893. 2008. 01012. x (2009).
6. Akuta, N. et al. Association of amino acid substitution pattern in core protein of hepatitis C virus genotype 1b high viral load and non-virological response to interferon-ribavirin combination therapy. Intervirology 48, 372-380, doi: 10. 1159/000086064 (2005).
7. Okanoue, T. et al. Predictive values of amino acid sequences of the core and NS5A regions in antiviral therapy for hepatitis C: a Japanese multi-center study. J. Gastroenterol. 44, 952-963, doi: 10. 1007/s00535-009-0087-x (2009).
8. Mori, N. et al. Randomized trial of high-dose interferon-alpha-2b combined with ribavirin in patients with chronic hepatitis C: Correlation between amino acid substitutions in the core/NS5A region and virological response to interferon therapy. J. Med. Virol. 81, 640-649, doi: 10. 1002/jmv. 21438 (2009).
9. Enomoto, N. & Maekawa, S. HCV genetic elements determining the early response to peginterferon and ribavirin therapy. Intervirology 53, 66-69, doi: 10. 1159/000252787 (2010).
10. Nakamoto, S. et al. Association between mutations in the core region of hepatitis C virus genotype 1 and hepatocellular carcinoma development. J. Hepatol. 52, 72-78, doi: 10. 1016/j. jhep. 2009. 10. 001 (2010).
11. Akuta, N. et al. Amino acid substitutions in hepatitis C virus core region predict hepatocarcinogenesis following eradication of HCV RNA by antiviral therapy. J. Med. Virol. 83, 1016-1022, doi: 10. 1002/jmv. 22094 (2011).
12. El-Shamy, A. et al. Sequence heterogeneity of NS5A and core proteins of hepatitis C virus and virological responses to pegylatedinterferon/ ribavirin combination therapy. Microbiol. Immunol. 55, 418-426, doi: 10. 1111/j. 1348-0421. 2011. 00331. x (2011).
13. Hayashi, K. et al. Mutations in the core and NS5A region of hepatitis C virus genotype 1b and correlation with response to pegylated-interferon-alpha 2b and ribavirin combination therapy. J. Viral Hepat. 18, 280-286, doi: 10. 1111/j. 1365-2893. 2010. 01305. x (2011).
14. El-Shamy, A. et al. Polymorphisms of hepatitis C virus non-structural protein 5A and core protein and clinical outcome of pegylated-interferon/ribavirin combination therapy. Intervirology 55, 1-11, doi: 10. 1159/000322219 (2012).
15. Akuta, N. et al. Complicated relationships of amino acid substitution in hepatitis C virus core region and IL28B genotype influencing hepatocarcinogenesis. Hepatology 56, 2134-2141, doi: 10. 1002/hep. 25949 (2012).
16. Seko, Y. et al. Amino acid substitutions in the hepatitis C Virus core region and lipid metabolism are associated with hepatocarcinogenesis in nonresponders to interferon plus ribavirin combination therapy. Intervirology 56, 13-21, doi: 10. 1159/000339993 (2013).
17. El-Shamy, A. et al. Polymorphisms of the core, NS3, and NS5A proteins of hepatitis C virus genotype 1b associate with development of hepatocellular carcinoma. Hepatology 58, 555-563, doi: 10. 1002/hep. 26205 (2013).
18. Miura, M. et al. Deep-sequencing analysis of the association between the quasispecies nature of the hepatitis C virus core region and disease progression. J. Virol. 87, 12541-12551, doi: 10. 1128/JVI. 00826-13 (2013).
19. Hijikata, M. et al. Proteolytic processing and membrane association of putative nonstructural proteins of hepatitis C virus. Proc. Natl. Acad. Sci. USA. 90, 10773-10777 (1993).
20. Grakoui, A., Wychowski, C., Lin, C., Feinstone, S. M. & Rice, C. M. Expression and identification of hepatitis C virus polyprotein cleavage products. J. Virol. 67, 1385-1395 (1993).
21. Miyanari, Y. et al. The lipid droplet is an important organelle for hepatitis C virus production. Nat. Cell Biol. 9, 1089-1097, doi: 10. 1038/ncb1631 (2007).
22. Masaki, T. et al. Interaction of hepatitis C virus nonstructural protein 5A with core protein is critical for the production of infectious virus particles. J. Virol. 82, 7964-7976, doi: 10. 1128/JVI. 00826-08 (2008).
23. Ray, R. B., Lagging, L. M., Meyer, K. & Ray, R. Hepatitis C virus core protein cooperates with ras and transforms primary rat embryo fibroblasts to tumorigenic phenotype. J. Virol. 70, 4438-4443 (1996).
24. Moriya, K. et al. Hepatitis C virus core protein induces hepatic steatosis in transgenic mice. J. Gen. Virol. 78 ( Pt 7), 1527-1531 (1997).
25. Moriya, K. et al. The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice. Nat. Med. 4, 1065-1067, doi: 10. 1038/2053 (1998).
26. Aoki, H., Hayashi, J., Moriyama, M., Arakawa, Y. & Hino, O. Hepatitis C virus core protein interacts with 14-3-3 protein and activates the kinase Raf-1. J. Virol. 74, 1736-1741 (2000).
27. Hayashi, J. et al. Hepatitis C virus core protein activates the MAPK/ERK cascade synergistically with tumor promoter TPA, but not with epidermal growth factor or transforming growth factor alpha. Hepatology 32, 958-961, doi: 10. 1053/jhep. 2000. 19343 (2000).
28. Honda, M. et al. Hepatitis C virus core protein induces apoptosis and impairs cell-cycle regulation in stably transformed Chinese hamster ovary cells. Hepatology 31, 1351-1359, doi: 10. 1053/jhep. 2000. 7985 (2000).
29. Moriishi, K. et al. Proteasome activator PA28gamma-dependent nuclear retention and degradation of hepatitis C virus core protein. J. Virol. 77, 10237-10249 (2003).
30. Tsutsumi, T. et al. Hepatitis C virus core protein activates ERK and p38 MAPK in cooperation with ethanol in transgenic mice. Hepatology 38, 820-828, doi: 10. 1053/jhep. 2003. 50399 (2003).
31. Miyoshi, H. et al. Hepatitis C virus core protein exerts an inhibitory effect on suppressor of cytokine signaling (SOCS)-1 gene expression. J. Hepatol. 43, 757-763, doi: 10. 1016/j. jhep. 2005. 03. 028 (2005).
32. Kanda, T., Steele, R., Ray, R. & Ray, R. B. Hepatitis C virus core protein augments androgen receptor-mediated signaling. J. Virol. 82, 11066-11072, doi: 10. 1128/JVI. 01300-08 (2008).
33. Tanaka, N., Moriya, K., Kiyosawa, K., Koike, K. & Aoyama, T. Hepatitis C virus core protein induces spontaneous and persistent activation of peroxisome proliferator-activated receptor alpha in transgenic mice: implications for HCV-associated hepatocarcinogenesis. Int. J. Cancer 122, 124-131, doi: 10. 1002/ijc. 23056 (2008).
34. Angus, A. G. et al. Requirement of cellular DDX3 for hepatitis C virus replication is unrelated to its interaction with the viral core protein. J. Gen. Virol. 91, 122-132, doi: 10. 1099/vir. 0. 015909-0 (2010).
35. Benzoubir, N. et al. HCV core-mediated activation of latent TGF-beta via thrombospondin drives the crosstalk between hepatocytes and stromal environment. J. Hepatol. 59, 1160-1168, doi: 10. 1016/j. jhep. 2013. 07. 036 (2013).
36. Stone, A. E. et al. Hepatitis C virus core protein inhibits interferon production by a human plasmacytoid dendritic cell line and dysregulates interferon regulatory factor-7 and signal transducer and activator of transcription (STAT) 1 protein expression. PLoS One 9, e95627, doi: 10. 1371/journal. pone. 0095627 (2014).
37. Park, S. H. & Rehermann, B. Immune responses to HCV and other hepatitis viruses. Immunity 40, 13-24, doi: 10. 1016/j. immuni. 2013. 12. 010 (2014).
38. Horner, S. M. & Gale, M., Jr. Regulation of hepatic innate immunity by hepatitis C virus. Nat. Med. 19, 879-888, doi: 10. 1038/ nm. 3253 (2013).
39. Garaigorta, U. & Chisari, F. V. Hepatitis C virus blocks interferon effector function by inducing protein kinase R phosphorylation. Cell Host Microbe 6, 513-522, doi: 10. 1016/j. chom. 2009. 11. 004 (2009).
40. Kang, W. et al. Hepatitis C Virus Attenuates Interferon-Induced MHC Class I Expression and Decreases CD8 T-Cell Effector Functions. Gastroenterology 146, 1351-1360, doi: 10. 1053/j. gastro. 2014. 01. 054 (2014).
41. El-Shamy, A. & Hotta, H. Impact of hepatitis C virus heterogeneity on interferon sensitivity: an overview. World J. Gastroenterol. 20, 7555-7569, doi: 10. 3748/wjg. v20. i24. 7555 (2014).
42. Wakita, T. et al. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat. Med. 11, 791-796, doi: 10. 1038/nm1268 (2005).
43. Funaoka, Y. et al. Analysis of interferon signaling by infectious hepatitis C virus clones with substitutions of core amino acids 70 and 91. J. Virol. 85, 5986-5994, doi: 10. 1128/jvi. 02583-10 (2011).
44. Ikeda, F. et al. Amino acid substitutions of hepatitis C virus core protein are not associated with intracellular antiviral response to interferon-alpha in vitro. Liver Int 30, 1324-1331, doi: 10. 1111/j. 1478-3231. 2010. 02299. x (2010).
45. Hiraga, N. et al. Impact of viral amino acid substitutions and host interleukin-28b polymorphism on replication and susceptibility to interferon of hepatitis C virus. Hepatology 54, 764-771, doi: 10. 1002/hep. 24453 (2011).
46. Zhong, J. et al. Robust hepatitis C virus infection in vitro. Proc. Natl. Acad. Sci. USA. 102, 9294-9299, doi: 10. 1073/pnas. 0503596102 (2005).
47. Akazawa, D. et al. CD81 expression is important for the permissiveness of Huh7 cell clones for heterogeneous hepatitis C virus infection. J. Virol. 81, 5036-5045, doi: 10. 1128/jvi. 01573-06 (2007).
48. Kato, T. et al. Cell culture and infection system for hepatitis C virus. Nat. Protoc. 1, 2334-2339, doi: 10. 1038/nprot. 2006. 395 (2006).
49. Kato, T. et al. Sequence analysis of hepatitis C virus isolated from a fulminant hepatitis patient. J. Med. Virol. 64, 334-339 (2001).
50. Aoyagi, K. et al. Development of a simple and highly sensitive enzyme immunoassay for hepatitis C virus core antigen. J. Clin. Microbiol. 37, 1802-1808 (1999).
51. Murayama, A et al. Japanese reference panel of blood specimens for evaluation of hepatitis C virus RNA and core antigen quantitative assays. J. Clin. Microbiol. 50, 1943-1949, doi: 10. 1128/JCM. 00487-12 (2012).
52. Kato, T. et al. Hepatitis C virus JFH-1 strain infection in chimpanzees is associated with low pathogenicity and emergence of an adaptive mutation. Hepatology 48, 732-740, doi: 10. 1002/hep. 22422 (2008).
53. Saeed, M. et al. In vivo adaptation of hepatitis C virus in chimpanzees for efficient virus production and evasion of apoptosis. Hepatology 54, 425-433, doi: 10. 1002/hep. 24399 (2011).